REIC gene therapy - Momotaro-Gene

Drug Profile

REIC gene therapy - Momotaro-Gene

Alternative Names: Ad5-SGE-REIC/Dkk-3; DKK3 gene therapy - Momotaro-Gene; MTG-201; REIC/Dkk-3 gene therapy

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Momotaro-Gene
  • Developer Icahn School of Medicine at Mount Sinai; Momotaro-Gene
  • Class Antineoplastics; Cancer vaccines; Gene therapies
  • Mechanism of Action Apoptosis stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Prostate cancer
  • Preclinical Hepatocellular carcinoma
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Japan (Intratumoural, Injection)
  • 21 Aug 2015 MTG 201 receives Orphan Drug status for Mesothelioma in USA
  • 21 Aug 2013 Momotaro-Gene and Mount Sinai School of Medicine terminate a phase I trial for Prostate cancer in the US (NCT01197209)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top